Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Value-Based Cancer Care

- PMLiVE

MIT study finds drug candidate reduces inflammation in Alzheimer’s models

The candidate significantly reduced inflammation and improved cognitive functions

- PMLiVE

BMS pays Zenas $50m upfront for regional rights to autoimmune disease antibody

The company will gain exclusive rights to develop and commercialise obexelimab

- PMLiVE

Seagen and Genmab’s Tivdak shows promise in phase 3 cervical cancer trial

The drug received FDA accelerated approval in 2021 to treat patients with advanced disease

bubble-chart-conference-attendance-preference

Pharma conference trends and themes in the last two years

We take an in-depth look at the way Pharma conferences have changed in the last two years and how that’s impacted attendance, themes and format.

Mednet

Embracing the Patient Voice Within Publications

This whitepaper will explore multidisciplinary perspectives on how we can better engage patient communities in publications to optimize the value of their contributions, while navigating any uncertainties and reluctance from...

OPEN Health

Navigating the nocebo effect through patient engagement is the key to setting patients up for success

If you're interested in delving deeper into this topic and understanding how patient engagement can effectively navigate the nocebo effect, we invite you to explore our latest whitepaper.

OPEN Health

- PMLiVE

Medscape Medical Affairs is Advancing Equity in Clinical Trials

Clinical trials are not just a necessary step in bringing a new drug or device to market, but a crucial investment on the part of the developing company. By 2025,...

Medscape Medical Affairs

- PMLiVE

Novartis sues US government over Medicare drug price negotiation programme

The action comes after the first drugs subject to pricing negotiations were announced

- PMLiVE

Roche announces positive phase 3 results for Alecensa in early-stage lung cancer

The drug is now the first ALK inhibitor to show disease-free survival benefit in this patient population

- PMLiVE

Bavarian Nordic’s COVID-19 booster ‘not suitable’ for emerging variants

Results showed that ABNCoV2 was not as effective against the circulating XBB.1.5 variant

- PMLiVE

GSK invests over $270m in vaccine manufacturing ahead of RSV vaccine launch

The unit will process the company’s vaccines, including Arexvy, Shingrix and Mosquirix

- PMLiVE

New UK study suggests brain fog after COVID-19 is linked to blood clots

High levels of two proteins caused excess blood clotting in people with long COVID

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links